- Home
- REVB vs TOVX Comparison
REVB vs TOVX Comparison
Compare REVB & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- TOVX
- Stock Information
- Founded
- REVB 2020
- TOVX 2001
- Country
- REVB United States
- TOVX United States
- Employees
- REVB N/A
- TOVX N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- TOVX Health Care
- Exchange
- REVB Nasdaq
- TOVX Nasdaq
- Market Cap
- REVB 3.8M
- TOVX 4.5M
- IPO Year
- REVB N/A
- TOVX 2006
- Fundamental
- Price
- REVB $2.38
- TOVX $0.44
- Analyst Decision
- REVB
- TOVX Hold
- Analyst Count
- REVB 0
- TOVX 1
- Target Price
- REVB N/A
- TOVX N/A
- AVG Volume (30 Days)
- REVB 283.8K
- TOVX 184.7K
- Earning Date
- REVB 08-08-2025
- TOVX 08-12-2025
- Dividend Yield
- REVB N/A
- TOVX N/A
- EPS Growth
- REVB N/A
- TOVX N/A
- EPS
- REVB N/A
- TOVX N/A
- Revenue
- REVB N/A
- TOVX N/A
- Revenue This Year
- REVB N/A
- TOVX N/A
- Revenue Next Year
- REVB N/A
- TOVX N/A
- P/E Ratio
- REVB N/A
- TOVX N/A
- Revenue Growth
- REVB N/A
- TOVX N/A
- 52 Week Low
- REVB $2.11
- TOVX $0.40
- 52 Week High
- REVB $168.00
- TOVX $7.25
- Technical
- Relative Strength Index (RSI)
- REVB 34.09
- TOVX 39.06
- Support Level
- REVB $2.97
- TOVX $0.45
- Resistance Level
- REVB $3.18
- TOVX $0.52
- Average True Range (ATR)
- REVB 0.22
- TOVX 0.03
- MACD
- REVB 0.05
- TOVX 0.00
- Stochastic Oscillator
- REVB 7.14
- TOVX 3.89
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.